Marijo Bilusic

Professor/ GU Oncology Team Lead

Sylvester Comprehensive Cancer Center, University of Miami

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Marijo Bilusic is a Professor and the GU Oncology Team Lead at the Sylvester Comprehensive Cancer Center, part of the University of Miami Health System. Based in the United States, Dr. Bilusic's research focuses on innovative approaches to cancer treatment, particularly in the areas of neoadjuvant and immunotherapy strategies for prostate and colorectal cancers. His recent publications explore emerging therapies, biomarkers, and the effectiveness of combination treatments in metastatic cancer patients.

Articles (12)

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (2)

Margaret Gatti-Mays

Assistant Professor

Ohio State University

UNITED STATES

View details

Eric Ross

Research Professor

Fox Chase Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marijo Bilusic

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Overcoming common emerging barriers to effective neoadjuvant immunotherapies

A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors

The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?

What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?

A Randomized Phase II Trial of mFOLFOX6+Bevacizumab Alone or with AdCEA Vaccine plus Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer

The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study

Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Collaborators (2)

Margaret Gatti-Mays

Eric Ross

Make your next move.